Triptolide has been used in trials studying the treatment of HIV, Crohn's Disease, Intestinal Diseases, Gastrointestinal Diseases, and Digestive System Diseases, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Triptolide. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Triptolide. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Triptolide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Triptolide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Triptolide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Triptolide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Triptolide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Triptolide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Triptolide. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triptolide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Triptolide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triptolide. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triptolide. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Triptolide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triptolide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triptolide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Triptolide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Triptolide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Triptolide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triptolide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Triptolide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triptolide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Triptolide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Triptolide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triptolide. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triptolide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Triptolide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Triptolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Triptolide. |
| Cladribine | Triptolide may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Triptolide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Triptolide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Triptolide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Triptolide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Triptolide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Triptolide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Triptolide. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Triptolide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Triptolide. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Triptolide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Triptolide. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Triptolide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Triptolide. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Triptolide. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Triptolide. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Triptolide. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Triptolide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Triptolide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Triptolide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Triptolide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Triptolide. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Triptolide. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Triptolide. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Triptolide. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Triptolide. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Triptolide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Triptolide. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Triptolide. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Triptolide. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Triptolide. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Triptolide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Triptolide. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Triptolide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Triptolide. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Triptolide. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Triptolide. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Triptolide. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Triptolide. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Triptolide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Triptolide. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Triptolide. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Triptolide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Triptolide. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Triptolide. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Triptolide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Triptolide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Triptolide. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Triptolide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Triptolide. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Triptolide. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Triptolide. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Triptolide. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Triptolide. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Triptolide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Triptolide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Triptolide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Triptolide. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Triptolide. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Triptolide. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Triptolide. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Triptolide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Triptolide. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Triptolide. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Triptolide. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Triptolide. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Triptolide. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptolide. |
| Docetaxel | The risk or severity of adverse effects can be increased when Docetaxel is combined with Triptolide. |
| Dasatinib | The risk or severity of adverse effects can be increased when Dasatinib is combined with Triptolide. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Triptolide. |